[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-cognitive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-cognitive-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100614447","phase-2-fisetin-in-mild-alzheimers-disease-100614447",false,"NCT07279714","Fisetin in Mild Alzheimer's Disease","Fisetin Intervention Study in Mild Alzheimer's Disease","FIS-AD","Inclusion Criteria:\n\n* Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia\n* Moca score of 11 or higher\n* Stable psychotropics and cognitive enhancing medications\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to fisetin\n* Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial\n* Unstable medical disorders\n* Ongoing treatment for active infection with antibiotics\u002Fantifungals\n* Ongoing treatment for cancer\n* Active alcohol or substance use disorder\n* Recent active bleeding\n* Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin\n* Use within the last month of other senolytic supplements, antioxidant supplements, natural health products\n* Other neurologic or neurodegenerative conditions impacting cognition\n* Active Major Depressive Episode, active suicidal thoughts or psychosis\n* Any thing that would preclude the ability to undergo an MRI scan","ALL","60 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.",[27,28,29,30,31,32,33],"Alzheimer s Disease","Alzheimer Dementia","Alzheimer Dementia (AD)","Alzheimer Disease","Mild Cognitive Disorder","Neurocognitive Disorders, Mild","Neurocognitive Disorder",[35,36,37,38],"fisetin","alzheimer's disease","safety","tolerability","RECRUITING","2026-04-10",{"date":42,"type":43},"2026-04-13","ACTUAL",{"date":45,"type":43},"2026-01-27",{"date":47,"type":21},"2026-11",{"name":49,"class":50},"Sunnybrook Health Sciences Centre","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100609344","study-on-the-effect-of-online-cognitive-training-doses-on-cognitive-function-in-individuals-with-mild-cognitive-decline-100609344","NCT07213362","Study on the Effect of Online Cognitive Training Doses on Cognitive Function in Individuals With Mild Cognitive Decline","Study on the Effect of Different Doses of Computerized Cognitive Training on Cognitive Function in Patients With Mild Cognitive Impairment: An Open-Label, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 60 years.\n* Self-reported cognitive decline, confirmed by an informant.\n* Montreal Cognitive Assessment (MoCA) score of 19-25, adjusted for years of education (+1 point for 12 years or less).\n* Ability to complete activities of daily living independently.\n* Possesses basic communication skills and is able to cooperate with the study procedures.\n* Voluntarily agrees to participate in the study and signs the informed consent form.\n\nExclusion Criteria:\n\n* Presence of underlying neurological diseases that may impair cognitive function, including but not limited to dementia syndrome, Parkinson's disease, epilepsy, and cerebrovascular disease.\n* Presence of severe or unstable organic diseases such as cancer, hydrocephalus, history of central nervous system tumors, or acute brain injury\u002Finfection.\n* Diagnosis of severe mental illness such as major depressive disorder, schizophrenia, schizoaffective disorder, or bipolar disorder.\n* Presence of severe visual or hearing impairment, or other physical conditions that may interfere with the completion of the study.\n* Participation in any other clinical trial within the past 3 months.\n* Having received transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), light therapy, or having taken medications that could significantly affect cognitive function (e.g., nootropics, psychoactive drugs, anticholinergic drugs, benzodiazepines) for any reason within the past 6 months.\n* History of alcohol dependence or substance abuse.\n* Consumption of alcohol or other substances that affect cognitive function, such as caffeine or cocaine, within 24 hours prior to the cognitive assessment.\n\nAny other conditions that the investigator deems unsuitable for participation in this study.",{"count":60,"type":21},234,[62],"NA","The primary questions that this clinical trial aims to answer are:\n\nTo compare the differences in the efficacy of different doses of Computerized Cognitive Training (CCT) in improving cognitive function among patients with Mild Cognitive Impairment (MCI), and to explore the potential optimal intervention dose.\n\nTo analyze the interaction between individual characteristics and the intervention dose of CCT.\n\nTo compare the improvement in functional activity ability of MCI patients among different CCT intervention dose groups.\n\nTo compare the symptoms of depression and anxiety among different CCT intervention dose groups.\n\nTo evaluate the adherence to different doses of CCT intervention.\n\nParticipants will:\n\nReceive CCT intervention at varying durations and frequencies over a 12-week period, and will be followed up for cognitive function, functional activity ability, etc., at weeks 4, 12, and 24.",[31],"NOT_YET_RECRUITING","2025-10-01",{"date":68,"type":43},"2025-10-08",{"date":68,"type":21},{"date":71,"type":21},"2026-12",{"name":73,"class":50},"Peking University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":51},"100420450","analysis-of-motor-skills-in-subjects-aged-55-and-over-the-role-of-cognitive-abilities-for-planning-movement-100420450","NCT04754906","Analysis of Motor Skills in Subjects Aged 55 and Over: the Role of Cognitive Abilities for Planning Movement.","Vieillissement","Inclusion Criteria:\n\n1. Neurotypical subjects group:\n\n   * Person aged 18 to 40 years\n   * Person who has given oral consent\n   * Affiliated to national health insurance\n   * Right-handed person\n2. Group of elderly neurotypical subjects:\n\n   * Person over 55 years of age\n   * Person who has given oral consent\n   * Affiliated to national health insurance\n   * No cognitive problems (MMSE score \\>26)\n   * Right-handed person\n3. Elderly mild cognitive disorder subject group:\n\n   * Person over 55 years of age\n   * Person who has given oral consent\n   * Diagnosis of Mild Cognitive Disorder made by a neurologist at the Centre Mémoire Ressources et Recherche (CMRR) of the University Hospital of Dijon, following the recommendations of the National Institute for Aging and Alzheimer's Association (Albert et al., 2011) This diagnosis is based on psychometric tests, brain imaging and the evolution of cognitive disorders, including an MMSE test.\n   * Right-handed person\n\nExclusion Criteria:\n\n* Neurological or psychiatric history with the exception of the TCL group.\n* Follow-up of drug treatment in the last three months that may affect cognitive and\u002For motor skills.\n* Received a shoulder prosthesis on the dominant side.\n* Received a hip and\u002For knee replacement less than a year ago.\n* Disabling joint disease of the hip or knee shoulder\n* Protected adults (curatorship, guardianship)\n* Person deprived of their liberty b judicial or administrative decision\n* Pregnant, parturient or breastfeeding woman\n* Major unable to consent",true,"18 Years",{"count":84,"type":21},684,"OBSERVATIONAL","Falling is an event that is more frequent and severe in older age. It can lead to a loss of autonomy and a decrease in quality of life. It is therefore important to understand this phenomenon in order to better prevent it. Among the multiple risk factors associated with falling, recent research has shown a link between the decline in cognitive abilities (i.e., the mental processes that form our knowledge, such as memory) and the risk of falling. However, the impact of this cognitive decline on motor skills is still poorly understood. The purpose of this research is to study how the changes induced by aging affect motor skills. This would make it possible to take a new look at the phenomenon of falls occurring in the elderly and, in the long term, to improve the prevention and rehabilitation.",[31],"2025-09-17",{"date":90,"type":43},"2025-09-22",{"date":92,"type":43},"2021-01-25",{"date":94,"type":21},"2028-12",{"name":96,"class":50},"Centre Hospitalier Universitaire Dijon"]